Triad Wealth Partners LLC Makes New Investment in Agilent Technologies, Inc. (NYSE:A)

Triad Wealth Partners LLC purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,903 shares of the medical research company’s stock, valued at approximately $256,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA lifted its stake in shares of Agilent Technologies by 3.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,589,874 shares of the medical research company’s stock valued at $2,314,784,000 after acquiring an additional 525,214 shares during the last quarter. FMR LLC lifted its stake in shares of Agilent Technologies by 62.2% in the 3rd quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock valued at $191,193,000 after acquiring an additional 493,947 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new stake in shares of Agilent Technologies in the 3rd quarter valued at about $49,449,000. Van ECK Associates Corp increased its holdings in Agilent Technologies by 8.7% during the 4th quarter. Van ECK Associates Corp now owns 3,235,263 shares of the medical research company’s stock valued at $434,625,000 after purchasing an additional 258,358 shares during the period. Finally, Jennison Associates LLC increased its holdings in Agilent Technologies by 63.3% during the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after purchasing an additional 227,431 shares during the period.

Agilent Technologies Stock Up 2.9 %

A stock opened at $126.64 on Thursday. Agilent Technologies, Inc. has a twelve month low of $121.45 and a twelve month high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market cap of $36.11 billion, a PE ratio of 29.11, a price-to-earnings-growth ratio of 3.45 and a beta of 1.11. The business has a 50 day moving average of $140.03 and a 200 day moving average of $138.87.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. On average, research analysts forecast that Agilent Technologies, Inc. will post 5.57 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

A has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. Citigroup boosted their price target on Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Robert W. Baird reduced their price target on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Finally, JPMorgan Chase & Co. reduced their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.